2016
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Fonarow GC, Thomas L, Singer DE, Freeman JV, Gersh BJ, Ansell J, Kowey PR, Mahaffey KW, Chan PS, Steinberg BA, Peterson ED, Piccini JP, Patients and Investigators O. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2016, 130: 449-456. PMID: 27888051, DOI: 10.1016/j.amjmed.2016.11.001.Peer-Reviewed Original ResearchConceptsOral anticoagulationAtrial fibrillationUntreated patientsSubsequent outcomesHigh riskAtrial fibrillation typeTransient ischemic attackAtrial fibrillation burdenBetter Informed TreatmentAtrial fibrillation patientsLow bleeding riskAmbulatory care sitesIschemic attackVASc scoreBleeding riskGuideline indicationsFibrillation patientsOutcomes RegistryCox regressionAdverse outcomesTreatment gapCare sitesNonsignificant trendPatientsCurrent community practice
2015
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes
Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation Cardiovascular Quality And Outcomes 2015, 8: 393-402. PMID: 26058720, DOI: 10.1161/circoutcomes.114.001303.Peer-Reviewed Original ResearchConceptsQuality of lifeAtrial fibrillationHigh riskAF patientsAF symptomsPatient outcomesSymptom severityAtrial Fibrillation EffectBorderline higher riskMajor adverse eventsBetter Informed TreatmentAtrial fibrillation symptomsCommunity-based studyAFEQT scoreEHRA classMajor bleedingMost patientsSymptom burdenAdverse eventsOutcomes RegistryCox regressionLife QuestionnaireFibrillation EffectInformed TreatmentPatients
2014
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaChi-Square DistributionDigoxinFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedPatient SelectionPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeConceptsRisk of deathIncident atrial fibrillationAtrial fibrillationDigoxin useHigh riskHeart failureIndependent associationPropensity score-matched adultsKaiser Permanente NorthernPrevious heart failureRetrospective cohort studyResearch Network StudySubgroups of ageCohort studyCox regressionAdverse outcomesRisk factorsHospitalizationFibrillationDigoxinDeathLimited dataAdultsRiskHigh rate
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial dataEffectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease
Chang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal Of Cardiac Failure 2013, 19: 176-182. PMID: 23482078, PMCID: PMC4126798, DOI: 10.1016/j.cardfail.2013.01.006.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseVentricular systolic dysfunctionΒ-blocker therapyHeart failure hospitalizationIncident heart failureHeart failureKidney diseaseSystolic dysfunctionFailure hospitalizationΒ-blockersLower riskKaiser Permanente Northern California systemLeft ventricular systolic dysfunctionLower crude riskCombined end pointΒ-blocker useGlomerular filtration rateAssociation of treatmentMultivariable adjustmentCrude riskMedication effectivenessCox regressionPotential confoundersFiltration rateMethodologic limitations